Kent C. Osborne

1.7k total citations
10 papers, 293 citations indexed

About

Kent C. Osborne is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Kent C. Osborne has authored 10 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in Kent C. Osborne's work include Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Kent C. Osborne is often cited by papers focused on Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Kent C. Osborne collaborates with scholars based in United States, United Kingdom and Norway. Kent C. Osborne's co-authors include Rachel Schiff, Meng Hong, Sanaa Nabha, Kaladhar B. Reddy, Anne E. Lykkesfeldt, Selina Glaros, Robert Paridaens, Patrick Neven, Björn Erikstein and Steven E. Come and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Kent C. Osborne

9 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kent C. Osborne United States	5	180	107	98	84	60	10	293
Wendy M. Swetzig United States	8	173 1.0×	238 2.2×	67 0.7×	93 1.1×	49 0.8×	16	342
Ilianna Zoi Greece	8	115 0.6×	125 1.2×	87 0.9×	69 0.8×	59 1.0×	10	262
Amir Bahreini United States	8	139 0.8×	166 1.6×	134 1.4×	133 1.6×	80 1.3×	16	327
Patrícia Izetti Brazil	6	140 0.8×	217 2.0×	59 0.6×	148 1.8×	39 0.7×	6	364
Chen-Hsiang Yeang Taiwan	7	67 0.4×	228 2.1×	52 0.5×	158 1.9×	35 0.6×	10	333
Tenghua Yu China	10	157 0.9×	213 2.0×	139 1.4×	127 1.5×	33 0.6×	30	380
Hongquan Zhang China	6	141 0.8×	150 1.4×	35 0.4×	61 0.7×	139 2.3×	7	295
Berthold Gierke Germany	8	105 0.6×	148 1.4×	51 0.5×	72 0.9×	32 0.5×	12	277
Uwe Heilenkötter Germany	9	122 0.7×	140 1.3×	22 0.2×	90 1.1×	59 1.0×	15	265
Tyler Robinson United States	6	168 0.9×	191 1.8×	20 0.2×	104 1.2×	66 1.1×	10	316

Countries citing papers authored by Kent C. Osborne

Since Specialization

Citations

This map shows the geographic impact of Kent C. Osborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kent C. Osborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kent C. Osborne more than expected).

Fields of papers citing papers by Kent C. Osborne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kent C. Osborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kent C. Osborne. The network helps show where Kent C. Osborne may publish in the future.

Co-authorship network of co-authors of Kent C. Osborne

This figure shows the co-authorship network connecting the top 25 collaborators of Kent C. Osborne. A scholar is included among the top collaborators of Kent C. Osborne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kent C. Osborne. Kent C. Osborne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Shafaee, Maryam Nemati, et al.. (2022). Abstract OT2-28-01: A phase 2 study of sitravatinib in metastatic, pre-treated, triple negative breast cancer, NCT # 04123704. Cancer Research. 82(4_Supplement). OT2–28. 1 indexed citations

Marusyk, Andriy, Doris P. Tabassum, Michalina Janiszewska, et al.. (2016). Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 76(22). 6495–6506. 96 indexed citations

Brouckaert, Olivier, Robert Paridaens, Giuseppe Floris, et al.. (2012). A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Annals of Oncology. 24(1). 47–53. 46 indexed citations

Makris, Andreas, Chad J. Creighton, Kent C. Osborne, et al.. (2007). Predictive gene expression patterns of response to adriamycin and cyclophosphamide (AC) in human breast cancers. Journal of Clinical Oncology. 25(18_suppl). 527–527.

Nabha, Sanaa, Selina Glaros, Meng Hong, et al.. (2005). Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 24(19). 3166–3176. 68 indexed citations

Osborne, Kent C.. (2005). S8 Endocrine Responsiveness: Understanding How Progesterone Receptor Can be Used to Select Endocrine Therapy. The Breast. 14. S5–S5. 3 indexed citations

Robertson, J.F.R., Björn Erikstein, Kent C. Osborne, et al.. (2004). Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer. Clinical Pharmacokinetics. 43(8). 529–538. 71 indexed citations

Osborne, Kent C.. (2003). Molecular mechanisms of hormonal resistance in breast cancer: Cross talk between growth factor and estrogen receptor pathways. The Breast. 12. S3–S3. 1 indexed citations

Margolin, Kim, Stephanie Green, Kent C. Osborne, et al.. (1994). Phase II Trial of 5-Fluorouracil and High-Dose Folinic Acid as First- or Second-Line Therapy for Advanced Breast Cancer. American Journal of Clinical Oncology. 17(2). 175–180. 5 indexed citations

10.

Robert, Nicholas J., William S. Dalton, Kent C. Osborne, & Martin D. Abeloff. (1989). Therapy in Premenopausal Women with Advanced, Oestrogen Positive or/and Progesterone Positive Breast Cancer: Surgical Oophorectomy versus the LHRH Analogue, Zoladex. Hormone Research. 32(1). 221–222. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact